Q-Line Biotech Ltd
Incorporated in 2010, Q-Line Biotech Ltd.
is engaged in the business of developing, manufacturing and marketing a diverse
range of reagents.[1]
- Market Cap ₹ 800 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 17.7
- Book Value ₹
- Dividend Yield %
- ROCE 24.7 %
- ROE 25.6 %
- Face Value ₹ 10.0
Pros
Cons
- Debtor days have increased from 69.9 to 96.2 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 183 | 203 | 314 | |
| 149 | 165 | 239 | |
| Operating Profit | 34 | 38 | 75 |
| OPM % | 18% | 19% | 24% |
| 2 | 3 | -8 | |
| Interest | 4 | 6 | 15 |
| Depreciation | 2 | 4 | 7 |
| Profit before tax | 30 | 31 | 44 |
| Tax % | 28% | 29% | 45% |
| 32 | 34 | 28 | |
| EPS in Rs | 203.81 | 218.67 | 178.60 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 2 | 2 | 2 |
| Reserves | 126 | 160 | 188 |
| 74 | 97 | 166 | |
| 51 | 81 | 99 | |
| Total Liabilities | 252 | 339 | 455 |
| 23 | 60 | 92 | |
| CWIP | 12 | 19 | 63 |
| Investments | 16 | 29 | 0 |
| 201 | 232 | 301 | |
| Total Assets | 252 | 339 | 455 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 25 | -24 | -1 | |
| -26 | -45 | -59 | |
| 26 | 17 | 53 | |
| Net Cash Flow | 25 | -52 | -7 |
| Free Cash Flow | -5 | -72 | -58 |
| CFO/OP | 111% | -39% | 7% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 66 | 47 | 96 |
| Inventory Days | 180 | 413 | 226 |
| Days Payable | 164 | 232 | 139 |
| Cash Conversion Cycle | 82 | 228 | 183 |
| Working Capital Days | -44 | 51 | 45 |
| ROCE % | 16% | 25% |
Business Profile:[1]
Q-Line Biotech is an Indian in-vitro
diagnostics (IVD) company engaged
in developing, manufacturing, marketing
and distributing diagnostic reagents, consumables, point-of-care (POC)
devices and diagnostic equipment.
The company primarily serves
diagnostic laboratories, hospitals
and medical colleges through
a B2B distribution-led model.